Skip to main content
Premium Trial:

Request an Annual Quote

Osmetech Expects US IPO Price of $8 to $10 per Share

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Osmetech has filed with the US Securities and Exchange Commission an amended prospectus for its proposed initial public offering in the US with an expected price range of $8 to $10 per share.

The British molecular diagnostics firm announced in March its plans to float in the US, cease trading on the AIM in London, and change its name to GenMark Diagnostics. It also said that it would move its headquarters to Pasadena, Calif.

According to the amended registration statement, Osmetech expects to 4.5 million shares of common stock in the offering. Current shareholders of Osmetech would receive one share of GenMark for every 230 shares of Osmetech held.

Osmetech said that a UK court hearing to sanction its plans has been scheduled for May 26, which would result in the plan proceeding on June 1 and the cancellation of trading on the AIM on June 2.

Osmetech expects to receive net proceeds of around $35 million from the US IPO. It intends to use those funds to develop a broad menu of tests for its XT-8 automated molecular diagnostics system, for continued development of that system, and for sales and marketing efforts.

For the three-month period ended March 31, Osmetech had total revenues of $399,264, compared to $188,300 for the first quarter of 2009. Its net loss for the quarter was $4.8 million, or $.68 per share, compared to a loss of $4.4 million, or $1.14 per share. As of March 31, it had $11.3 million in cash and cash equivalents.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.